国药科技股份(08156)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

08156 国药科技股份

已收盘 10-23 09:20:27

0.180

+0.000

0.00%

最高0.180	最低0.180	成交量0.00
今开0.180	昨收0.180	日振幅0.00%
总市值1.14亿	流通市值1.14亿	总股本6.34亿
成交额0.00	换手率0.00%	流通股本6.34亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"08156","market":"HK","secType":"STK","nameCN":"国药科技股份","latestPrice":0.18,"timestamp":1792718427384,"preClose":0.18,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":634000000,"shares":634000000,"eps":-0.014426,"marketStatus":"已收盘","change":0,"latestTime":"10-23 09:20:27","open":0.18,"high":0.18,"low":0.18,"amount":0,"amplitude":0,"askPrice":0.183,"askSize":60000,"bidPrice":0.165,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.014426,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"listingDate":1037030400000,"exchange":"SEHK","adjPreClose":0.18,"openAndCloseTimeList":[[1792719000000,1792728000000],[1792731600000,1792742400000]],"volumeRatio":0,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/08156/wiki","defaultTab":"wiki","newsList":[{"id":"1190884447","title":"国药科技股份发布2026年9月股份变动月报，股本维持200,000,000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190884447","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190884447?lang=zh_cn&edition=full","pubTime":"2026-10-07 14:05","pubTimestamp":1791353139,"startTime":"0","endTime":"0","summary":"国药科技股份于2026年10月7日公布2026年9月股份变动月报。公告显示，截至2026年9月30日，公司全体股东于2024年完成股本重组后，法定注册股本总额保持在200,000,000港元，分为普通股160,000,000港元及可换股优先股40,000,000港元，面值均为0.0125港元/股。相较上月，注册股本无新增或减少。公告显示，所有股份变动事项均已获得公司董事会正式授权批准，并按相关上市规则及适用法律法规办理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158027576","title":"国药科技股份更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1158027576","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158027576?lang=zh_cn&edition=full","pubTime":"2026-10-07 14:01","pubTimestamp":1791352883,"startTime":"0","endTime":"0","summary":"国药科技股份于2026年10月7日发布截至2026年8月31日的证券变动月报表。公告显示，公司注册股本及已发行股份在本月无变动，股本整体保持稳定。已发行股份方面，截至2026年8月31日，普通股维持在633,693,055股，优先股维持在1,480,151,050股，未出现新增发行或购回、注销、库存股份变动。于期权与激励计划方面，公司2021年购股权计划下，报告期末的已授予购股权数量为4,960,000份，可行使购股权对应4,960,000股，行使价每股港币1元。报告期内未有新增发行股份事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156818397","title":"国药科技股份7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1156818397","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156818397?lang=zh_cn&edition=full","pubTime":"2026-10-07 13:55","pubTimestamp":1791352552,"startTime":"0","endTime":"0","summary":"国药科技股份有限公司于2026年10月7日发布截至2026年7月31日的证券变动月报表。公告显示，公司法定股本总额保持在200,000,000港元，由12,800,000,000股每股面值0.0125港元的普通股及3,200,000,000股每股面值0.0125港元的可换股优先股构成。上述法定股本结构自2024年11月6日起生效。公司报告期内无新增股份发行、购回或注销交易，股本维持不变。国药科技股份在公告中确认，其所有股份发行均符合香港联合交易所有限公司《GEM上市规则》及相关法律法规规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144166378","title":"国药科技股份6月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1144166378","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144166378?lang=zh_cn&edition=full","pubTime":"2026-10-07 13:45","pubTimestamp":1791351936,"startTime":"0","endTime":"0","summary":"国药科技股份于2026年10月7日发布截至2026年6月30日的证券变动月报表。报告显示，公司2026年6月期间已发行股本及注册股本均未发生变化，股本架构保持稳定。其中，普通股于本月末的已发行股数为633,693,055股，与上月底保持相同；无投票权可换股优先股已发行数量同样维持1,480,151,050股未变。公告显示，本月并无新增发行、购回、注销或库藏股变动。本月已发行股本及库存股份的数量均未发生增减，普通股占公众持股比例约为24.95%。公告由执行董事郭淑仪签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154493810","title":"国药科技股份2026年5月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154493810","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154493810?lang=zh_cn&edition=full","pubTime":"2026-10-07 13:35","pubTimestamp":1791351343,"startTime":"0","endTime":"0","summary":"2026年10月7日，国药科技股份发布截至2026年5月31日止当月的证券变动月报表。报告显示，公司于本月无新发行股份、无股份回购或注销事宜，股本结构整体保持不变。截至2026年5月末，公司法定/注册股本为200,000,000港元，其中包括12,800,000,000股普通股及3,200,000,000股可换股优先股，均为每股面值0.0125港元。普通股方面，月末已发行股票数量维持在633,693,055股，呈库存股份持有量为0股。优先股方面，月末已发行可换股优先股数为1,480,151,050股，与上月保持一致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194383403","title":"国药科技股份更新2026年4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1194383403","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194383403?lang=zh_cn&edition=full","pubTime":"2026-10-07 13:00","pubTimestamp":1791349244,"startTime":"0","endTime":"0","summary":"国药科技股份有限公司于2026年10月7日发布截至2026年4月30日的股份变动月报表。报告期内，公司普通股及优先股的已发行数量与上月底保持一致，股本整体维持不变。公司普通股已发行股份数量在2026年4月末为633,693,055股，与上月底相同；优先股已发行股份为1,480,151,050股，亦无变化。公司于2021年采纳的购股权计划发生120,000份期权失效，月末剩余股份期权4,960,000份，均未行使或转换为实际发行股份。截至本月末，公司股本总数保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154586800","title":"国药科技股份更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154586800","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154586800?lang=zh_cn&edition=full","pubTime":"2026-10-07 12:55","pubTimestamp":1791348936,"startTime":"0","endTime":"0","summary":"国药科技股份于2026年10月7日发布截至2026年3月31日的股份变动月报表。公司股本总额继续维持在200,000,000港元，其中包括12,800,000,000股每股面值0.0125港元的普通股及3,200,000,000股每股面值0.0125港元的无投票权可换股优先股。与此同时，国药科技股份在2021年通过的购股权计划所涉股份期权维ides 5,080,000份，行使价为每股1港元，当月亦未产生新的行权或转让情形。公司在月报表中确认，本期所有发行及股份转让均符合法规及香港联交所相关上市规则。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193204134","title":"国药科技股份2026年2月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1193204134","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193204134?lang=zh_cn&edition=full","pubTime":"2026-10-07 12:45","pubTimestamp":1791348340,"startTime":"0","endTime":"0","summary":"国药科技股份有限公司于2026年10月7日发布了截至2026年2月28日的证券变动月报，综合披露普通股及可换股优先股等股本情况，报告期内并无新增发行或回购活动，股本保持稳定。报告期初与期末普通股法定注册股本合计16亿港元，可换股优先股法定注册股本合计4亿港元，均与上期保持一致。公告称，截至2026年2月末，公司不存在新发行、回购或已注销的股份，股本规模维持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193900356","title":"国药科技股份更新2026年1月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193900356","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193900356?lang=zh_cn&edition=full","pubTime":"2026-10-07 12:30","pubTimestamp":1791347459,"startTime":"0","endTime":"0","summary":"国药科技股份于2026年10月7日提交了截至2026年1月31日的股份变动月报表。公告披露，本月内公司注册股本与已发行股份总数均未发生变动，股本结构保持稳定。在发行股份方面，截至2026年1月31日，普通股已发行股份总数为633,693,055股，相较上月无新增发行或回购，也不存在库存股变化；优先股已发行股份为1,480,151,050股，同样未出现增减。目前可换股优先股总额为148,015,105港元，报告期内并无变动。本次公告由执行董事郭淑仪签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673083078","title":"国药科技股份(08156.HK)恢复公众持股量","url":"https://stock-news.laohu8.com/highlight/detail?id=2673083078","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673083078?lang=zh_cn&edition=full","pubTime":"2026-10-05 23:19","pubTimestamp":1791213572,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1197","08156","BK1172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673446083","title":"国药科技股份(08156.HK)公众持股量约25.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673446083","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673446083?lang=zh_cn&edition=full","pubTime":"2026-10-05 22:57","pubTimestamp":1791212221,"startTime":"0","endTime":"0","summary":"格隆汇10月5日丨国药科技股份(08156.HK)公告，公司获告知，独立非执行董事向碧伦及基于向提交的权益披露表，于2026年10月5日，于交易所内出售公司合共38万股普通股后，公司公众持股量已变为约25.01%，符合GEM上市规则第17.37B(1)条规定的25.0%最低公众持股量要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261005/32388210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1197","08156","BK1172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101224135","title":"国药科技股份（08156）恢复25.01%公众持股量 符合GEM上市规则要求","url":"https://stock-news.laohu8.com/highlight/detail?id=1101224135","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101224135?lang=zh_cn&edition=full","pubTime":"2026-10-05 22:35","pubTimestamp":1791210922,"startTime":"0","endTime":"0","summary":"国药科技股份有限公司10月5日公告称，继9月16日披露公司公众持股量不足后，经独立非执行董事向碧伦先生于2026年10月5日在联交所内累计出售38万股普通股后，公司公众持股量已提升至约25.01%，达到《GEM上市规则》第17.37B条规定的25.0%最低公众持股量要求。公司表示，目前已符合香港联交所GEM板最低公众持股量的监管要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671248942","title":"国药科技：2026财年净亏损910万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671248942","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671248942?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:26","pubTimestamp":1790691974,"startTime":"0","endTime":"0","summary":"南财智讯9月29日电，国药科技（08156.HK）公告，截至2026年6月30日止年度，本公司拥有人应占亏损约910万港元；收入约4560万港元，较2025财年同期的6130万港元减少约26%；毛利约640万港元，较2025财年同期的1420万港元减少约55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886779754.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886779754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK1172","08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172733849","title":"国药科技2026财年营收下滑26%  深化AI驱动医药供应链转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1172733849","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172733849?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:25","pubTimestamp":1790691908,"startTime":"0","endTime":"0","summary":"国药科技控股有限公司于截至2026年6月30日止财政年度内，在“科技赋能大健康”核心战略指引下，继续重点发展“大健康产业”与“医药供应链服务”两大主营业务，着力结合人工智能及大数据等技术，为供应链以及智能健康服务提供支持。整体来看，国药科技在2026财年营收与盈利能力均受到挑战，亏损加剧，资金与杠杆水平承压。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"国药科技2026财年营收下滑26%  深化AI驱动医药供应链转型","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113647163","title":"国药科技股份（08156）2026财年收入下滑26%，亏损同比扩大769%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113647163","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113647163?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:15","pubTimestamp":1790691336,"startTime":"0","endTime":"0","summary":"国药科技股份于截至二零二六年六月三十日止年度，录得收入约4,560.00万港元，较上年度的约6,130.00万港元下降约26%。受核心业务收入减少及成本上升等多重因素影响，公司年内亏损由上年的约137.00万港元扩大至约1,190.30万港元，同比增幅约769%，毛利则由上年的约1,420.00万港元降至约640.00万港元。销售及分销费用亦从约164.80万港元上升至约468.50万港元，增幅超过一倍。董事会对 ESG 投入最终责任，确保集团在环境与社会责任方面不断优化管理体系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"国药科技股份（08156）2026财年收入下滑26%，亏损同比扩大769%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669491356","title":"国药科技股份：2026财年净亏损910万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669491356","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669491356?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:52","pubTimestamp":1790261520,"startTime":"0","endTime":"0","summary":"南财智讯9月24日电，国药科技股份（08156.HK）公告，截至2026年6月30日止财年，本公司拥有人应占亏损约910万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609243883949785.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609243883949785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK1172","08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669459496","title":"国药科技股份(08156.HK)发布年度业绩 股东应占亏损914.2万港元 同比大幅增加954.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669459496","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669459496?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:13","pubTimestamp":1790259214,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1197","08156","BK1172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668392153","title":"国药科技股份(08156.HK)发盈警 预计年度股东应占亏损900万至1100万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668392153","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668392153?lang=zh_cn&edition=full","pubTime":"2026-09-18 22:11","pubTimestamp":1789740672,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["08156","BK1172","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163636537","title":"国药科技股份预警：全年亏损预计扩大，供应链收入下滑及推广费用攀升成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1163636537","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163636537?lang=zh_cn&edition=full","pubTime":"2026-09-18 22:04","pubTimestamp":1789740249,"startTime":"0","endTime":"0","summary":"国药科技股份（08156.HK）发布盈警公告，预期全年亏损幅度将较上年同期显著扩大。业绩转差的核心原因，在于供应链业务收入出现萎缩，叠加市场推广等相关成本持续走高，多重因素共同拖累了整体盈利表现。公司方面指出，除上述两项主要影响因素外，还有其他综合因素对财务状况构成压力，但具体明细尚未完全披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","BK1172","08156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186360667","title":"国药科技股份（08156）公示公眾持股量跌破25%下限 将于三个月内完成恢复","url":"https://stock-news.laohu8.com/highlight/detail?id=1186360667","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186360667?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:00","pubTimestamp":1789552841,"startTime":"0","endTime":"0","summary":"2026年9月16日，国药科技股份有限公司公告披露，截至公告日，公司公眾持股量约为24.95%，低于香港联交所GEM上市规则第17.37B条规定的25.0%最低公眾持股要求。公司已发行普通股总数为633,693,055股。公司表示，正研究恢复公眾持股量的方案，包括促使有关股东出售所持股份及／或向公眾发行新股份。公司预计将在公告日起三个月内完成恢复。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08156"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cvg.com.hk","stockEarnings":[{"period":"1week","weight":-0.1818},{"period":"1month","weight":-0.1509},{"period":"3month","weight":0.1043},{"period":"6month","weight":-0.3793},{"period":"1year","weight":-0.2623},{"period":"ytd","weight":-0.4}],"compareEarnings":[{"period":"1week","weight":-0.0469},{"period":"1month","weight":-0.0858},{"period":"3month","weight":-0.0813},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.1104},{"period":"ytd","weight":-0.1052}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药科技股份有限公司是一家主要从事大健康产业及药品供应链业务的投资控股公司。该公司通过三个部门运营业务。供应链服务分部从事提供供应链管理、数据分析及相关服务及贸易相关货品，以及贸易医疗及相关产品。互联网+解决方案服务分部从事提供互联网+解决方案服务，提供互联网相关解决方案服务。制造及分销个人防护装备分部从事制造及销售个人防护装备及消耗品以及其他相关货品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.123218},{"month":2,"riseRate":0.333333,"avgChangeRate":0.013986},{"month":3,"riseRate":0.25,"avgChangeRate":-0.077347},{"month":4,"riseRate":0.25,"avgChangeRate":-0.056954},{"month":5,"riseRate":0.458333,"avgChangeRate":0.091957},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.060911},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.007588},{"month":8,"riseRate":0.291667,"avgChangeRate":-0.014268},{"month":9,"riseRate":0.375,"avgChangeRate":0.070048},{"month":10,"riseRate":0.521739,"avgChangeRate":0.110099},{"month":11,"riseRate":0.409091,"avgChangeRate":0.077103},{"month":12,"riseRate":0.458333,"avgChangeRate":-0.001405}],"exchange":"SEHK","name":"国药科技股份","nameEN":"SINOPHARM TECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药科技股份(08156)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药科技股份(08156)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药科技股份,08156,国药科技股份股票,国药科技股份股票老虎,国药科技股份股票老虎国际,国药科技股份行情,国药科技股份股票行情,国药科技股份股价,国药科技股份股市,国药科技股份股票价格,国药科技股份股票交易,国药科技股份股票购买,国药科技股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药科技股份(08156)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药科技股份(08156)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}